MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/ajh.70347

Медицинская библиотека · American journal of hematology · 2026

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant.

Chen George L, Bassett Roland, Mehta Rohtesh S, Oran Betul, Khawaja Fareed, Ariza-Heredia Ella J, Aljawai Yosra, Olson Amanda, Daher May, Smallbone Portia, Rezvani Katayoun, Kebriaei Partow, Popat Uday, Champlin Richard, Chemaly Roy F, Shpall Elizabeth J

СтатьяПеревод в очереди

Аннотация

Graft versus host disease (GVHD) prophylaxis with posttransplant cyclophosphamide (ptCY) and cytomegalovirus (CMV) prophylaxis with letermovir have changed the clinical epidemiology of CMV infection. We studied the incidence, risk factors for, and outcomes of CMV infection after Day + 90 of allogeneic hematopoietic cell transplant (alloHCT). The patient cohort consisted of 2106 alloHCT patients treated from 2015 to 2022 with a single alloHCT. Fifty-seven percent of patients received ptCY. Forty-three percent of patients received letermovir. We performed landmark analysis of the cumulative incidence of CMV-emia with the competing risk of death from Day + 0 to +360 in 90-day intervals. Regression analyses of baseline and time-dependent covariates for CMV-emia and survival were performed for each interval. The cumulative incidence of CMV-emia (≥ 500 IU CMV DNA/mL) was associated with donor/recipient CMV serostatus. In the highest risk CMV serostatus donor negative and recipient positive (D-R+) group, the cumulative incidence was 24.3 (95% confidence interval [CI] 21.3-27.3), 9 (95% CI: 6.9-11.1), 5 (95% CI: 3.3-6.7), and 2.1 (95% CI: 0.9-3.3) from Day 0 to 90, 91 to 180, 181 to 270, and 271 to 360, respectively. The primary risk factors associated with CMV incidence were related to acute GVHD. PtCY was associated with a decreased risk of CMV infection. Letermovir prophylaxis did not associate with decreased CMV infection after Day + 90. In conclusion, the risk of CMV infection remains clinically significant until Day + 180, although this is affected by the GVHD status of the patient. Discontinuation of letermovir may be considered after Day + 180.

Для цитирования: Chen George L, Bassett Roland, Mehta Rohtesh S, Oran Betul, Khawaja Fareed, Ariza-Heredia Ella J, Aljawai Yosra, Olson Amanda, Daher May, Smallbone Portia, Rezvani Katayoun, Kebriaei Partow, Popat Uday, Champlin Richard, Chemaly Roy F, Shpall Elizabeth J. Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant.. American journal of hematology. 2026. DOI: 10.1002/ajh.70347.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.